Some of Advanced NMR's shareholders are not pleased with the company'splan to acquire the remaining shares outstanding of subsidiaryAdvanced Mammography Systems (SCAN 2/14/96). The Wilmington, MA,company announced last week that a class action lawsuit
Some of Advanced NMR's shareholders are not pleased with the company'splan to acquire the remaining shares outstanding of subsidiaryAdvanced Mammography Systems (SCAN 2/14/96). The Wilmington, MA,company announced last week that a class action lawsuit has beenfiled against it by shareholders who claim that the terms of thetransaction are unfair.
Advanced NMR now owns 61% of Advanced Mammography Systems andintends to acquire 100% of the MR mammography developer underthe buyout plan. The company said that it is preparing proxy materialsfor the merger, which will be proposed to AMS shareholders ata meeting to be held in late spring. It said that it believesthe terms of the acquisition are fair.
ANMR this month also released financial results for the firstquarter of 1996 (end-December) that show the positive contributionbeing made by Medical Diagnostics, which ANMR acquired last August(SCAN 5/10/95).
ANMR had revenues for the quarter of $6.2 million, of whichAdvanced NMR system sales contributed only $49,000 while the restcame from MDI's imaging services business. ANMR had a net lossof $1.6 million, compared with a net loss of $2.2 million in thesame quarter last year. The MDI business was profitable. ANMRexpects system sales to increase, as the company has a $4.8 millionbacklog, according to chairman and CEO Jack Nelson.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
Study of Ofatumumab for Multiple Sclerosis Shows 'Profoundly Suppressed MRI Lesion Activity'
April 17th 2024The use of continuous ofatumumab in patients within three years of a relapsing multiple sclerosis diagnosis led to substantial reductions in associated lesions on brain MRI scans, according to research recently presented at the American Academy of Neurology (AAN) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
2 Commerce Drive
Cranbury, NJ 08512